AnodyneWiki

Flurazepam

Flurazepam
Flurazepam
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass387.90 g/mol [1]
AppearanceWhite rods from ether-petroleum ether [1]
Melting point190-220 [1]
Solubility500 mg/mL (HCl salt) [1]
Predicted LogP3 [1]
Structural Identifiers
[]
Molecular formulaC21H23ClFN3O
IUPAC name7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
SMILESCCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
InChIInChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
InChIKeySAADBVWGJQAEFS-UHFFFAOYSA-N
CAS number17617-23-1
UNIIIHP475989U
PubChem CID3393
Pharmacokinetics[]
Elimination half-life2.3 hours, N-desalkylflurazepam: 47–100 hours
MetabolismLiver
ExcretionKidney
Routes of administrationBy mouth
Addiction liabilityModerate
Toxicity
[]
Mouse:
- ip: 290 mg/kg
- oral: 870 mg/kg
- iv: 84 mg/kg
 [1]

Flurazepam (also known as Insumin, Flurazepamum, Dalmane-R, Felison, Ro-5-6901/3, Dormodor, Apo Flurazepam, Flurazepam Mono Perchlorate, Mono-Perchlorate, Flurazepam or N05cd01) is a substance of the aniline and benzodiazepine class.

Chemistry

 []

Flurazepam is achiral.

Flurazepam matches Lipinski's rule of five.

There are currently 2 reagent-interactions on

ReagentColor changeDescription
Froehdeorange
Zimmermannviolet / purple

Pharmacology

Mechanism of action []

Flurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target37
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34
shared target34

Medical side effects []

59 side effects listed on drug labels in (flurazepam).

  • Agranulocytosis
  • Decreased appetite
  • Arthralgia
  • Musculoskeletal discomfort
  • Asthenia
  • Ataxia
  • Chest pain
  • Coma
  • Confusional state
  • Feeling abnormal
  • Constipation
  • Diarrhoea
  • Dizziness
  • Syncope
  • Lightheadedness
  • Somnolence
  • Dyspnoea
  • Dermatitis
  • Rash
  • Flushing
  • Hallucination
  • Headache
  • Dyspepsia
  • Hypotension
  • Irritability
  • Lethargy
  • Leukopenia
  • Nausea
  • Nervousness
  • Tension
  • Palpitations
  • Pruritus
  • Salivary hypersecretion
  • Withdrawal syndrome
  • Hyperhidrosis
  • Shock
  • Loss of consciousness
  • Vomiting
  • Dry mouth
  • Agitation
  • Excitement
  • Hyperkinesia
  • Blood alkaline phosphatase increased
  • Aspartate aminotransferase increased
  • Disorientation
  • Anxiety
  • Thinking abnormal
  • Mental disability
  • Dysarthria
  • Euphoric mood
  • Dysgeusia
  • Abdominal discomfort
  • Drug intolerance
  • Anaphylactic shock
  • Anaphylactoid reaction
  • Vision blurred
  • Gastrointestinal pain
  • Gait disturbance
  • Logorrhoea

Indications

  • Insomnia
  • Terminal insomnia

Subjective effects []

nervewing / Flurazepam []

 []

  • Brazil: Flurazepam is a B1.[3]
  • Canada: Flurazepam is a Schedule IV.
  • Germany: Flurazepam is Prescription only/Anlage III.
  • United States: Flurazepam is a Schedule IV under the "Controlled Substances Act".
  • Other: Flurazepam is a SE: Förteckning IV, In general: ℞ (Prescription only).[4]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 3393, Flurazepam. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3393
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Flurazepam. UNII: IHP475989U. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/IHP475989U
  3. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  4. Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. Läkemedelsverket. https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 18:00:26
drugsprook2026-11-20 18:00:22
erowidmissing (no Erowid substance of that name)2026-11-20 18:00:22
gsrsok2026-11-20 18:00:22
hmdbmissing (hmdb.ca refused automated access to HMDB0014828)2026-11-20 18:00:22
keggok2026-11-20 18:00:24
pubchemok2026-11-20 18:00:21
redditmissing (no r/tripreports posts mention it)2026-11-20 18:00:22
siderok2026-11-20 18:00:22
structureok2026-11-20 18:00:22
wikipediaok2026-11-20 18:00:22